Vol 49 No 02

In this interview, Emmanuel S. Antonarakis, MD, provides an overview of rucaparib (Rubraca) and olaparib (Lynparza), discusses the key trials that led to their approvals, and explains the urologist’s role in their use.

"It is essential for us to be vigilant about all the complications, whether local or systemic, associated with intravesical BCG," writes Badar M. Mian, MD.

"I have no problem with patients seeing everything in their chart. It is their medical record, after all. But I do think there should be some limitations on this access," writes Henry Rosevear, MD.

The provider said the patient failed to timely return for follow-up.

Analyses of data collected in a prospectively maintained database support the recommendation for urologists to consider the minimally invasive version of mini-percutaneous nephrolithotomy for stone removal in patients with medium-sized stones (10-20 mm).

Recent legislation appears to have delayed implementation of the new code.

"Everything comes down to patient selection and location of the stones," says one urologist.

The boost improved biochemical disease-free survival without negatively affecting safety and quality of life.

The trend in prostate cancer aligns with an overall decline in cancer-related suicide across all tumor types.

The study contradicts the findings from an Italian study published in 2020.

Minimally-invasive treatment with the iTind device (Medi-Tate) provides rapid and sustained improvement of LUTS in men with BPH, without adversely affecting patients’ sexual function, according to a recently published 12-month study.

A large review showed that cancer specific survival was improved in overweight and obese patients with renal cell carcinoma compared with patients with normal BMI.

Compared with the open procedure, robot-assisted simple prostatectomy was associated with a shorter median hospital stay.

Existing evidence does not clarify which patients with acute ureteral colic would benefit most from early surgical intervention.

The findings support continued investigation of the safety and efficacy of mirabegron in men with OAB and concurrent ED, says study author Arthur L. Burnett, II, MD, MBA.